These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HPV vaccines: what remains to be done? Interview by Lauren Constable. Zur Hausen H Expert Rev Vaccines; 2011 Nov; 10(11):1505-7. PubMed ID: 22043949 [No Abstract] [Full Text] [Related]
3. The rationale for implementation of HPV testing in routine cervical screening in Romania. Iancu LS; Ursu RG Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):293-6. PubMed ID: 24340506 [No Abstract] [Full Text] [Related]
5. Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention. Awolude OA; Morhason-Bello IO; Denny LA; Adewole IF Vaccine; 2013 Dec; 31 Suppl 5():vii-x. PubMed ID: 24331751 [No Abstract] [Full Text] [Related]
6. Human papillomavirus: current status and issues of vaccination. Malik H; Khan FH; Ahsan H Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639 [TBL] [Abstract][Full Text] [Related]
7. The Cape Town declaration on human papillomavirus related disease. Williamson AL; Garland S; Palefsky J; Rybicki E; Stanley M; de Sanjosé S Papillomavirus Res; 2018 Jun; 5():59-60. PubMed ID: 29294358 [No Abstract] [Full Text] [Related]
8. HPV-vaccine and screening programs: the new era of global prevention. Mariani L J Prev Med Hyg; 2009 Jun; 50(2):90-5. PubMed ID: 20099438 [No Abstract] [Full Text] [Related]
9. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297 [TBL] [Abstract][Full Text] [Related]
10. Limitations of human papillomavirus DNA testing in measuring previous exposure and vaccine protection. Brown B HIV Med; 2015 Aug; 16(7):455-6. PubMed ID: 26176296 [No Abstract] [Full Text] [Related]
11. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis. Wang H; Qiao YL Int J STD AIDS; 2008 Oct; 19(10):680-4. PubMed ID: 18824620 [TBL] [Abstract][Full Text] [Related]
12. The Expanded Impact of Human Papillomavirus Vaccine. Pahud BA; Ault KA Infect Dis Clin North Am; 2015 Dec; 29(4):715-24. PubMed ID: 26610422 [TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Hong AM; Grulich AE; Jones D; Lee CS; Garland SM; Dobbins TA; Clark JR; Harnett GB; Milross CG; O'Brien CJ; Rose BR Vaccine; 2010 Apr; 28(19):3269-72. PubMed ID: 20226244 [TBL] [Abstract][Full Text] [Related]
14. An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections. Garbuglia AR; Gentile M; Del Nonno F; Lorenzini P; Lapa D; Lupi F; Pinnetti C; Baiocchini A; Libertone R; Cicalini S; Capobianchi MR; Ammassari A J Clin Virol; 2015 Nov; 72():49-54. PubMed ID: 26397204 [TBL] [Abstract][Full Text] [Related]
15. Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. Dunne EF; Naleway A; Smith N; Crane B; Weinmann S; Braxton J; Steinau M; Unger ER; Markowitz LE J Infect Dis; 2015 Dec; 212(12):1970-5. PubMed ID: 26123561 [TBL] [Abstract][Full Text] [Related]
16. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Wong CA; Saraiya M; Hariri S; Eckert L; Howlett RI; Markowitz LE; Brotherton JM; Sinka K; Martinez-Montañez OG; Kjaer SK; Dunne EF Vaccine; 2011 Jan; 29(5):878-85. PubMed ID: 20971113 [TBL] [Abstract][Full Text] [Related]
17. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA. Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G; Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273 [TBL] [Abstract][Full Text] [Related]
18. HPV vaccine update: new indications and controversies. Mendoza N; Hernandez PO; Tyring SK Skin Therapy Lett; 2011 Sep; 16(8):1-3. PubMed ID: 22089414 [TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccine update. Gilmer LS Prim Care; 2015 Mar; 42(1):17-32. PubMed ID: 25634702 [TBL] [Abstract][Full Text] [Related]
20. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Goldstone SE; Vuocolo S Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]